Cubist is issuing a nationwide recall of four lots of its antibiotic injection Cubicin after one of the company’s CMOs had a manufacturing issue that caused glass particulates to contaminate the lots.
Haupt says it will become Europe’s second largest manufacturer of contraceptive pills as it gets set for production after winning a contract from a “large group” in Ireland.
Amgen spent $10.4bn (€7.8bn) this week on Onyx Pharmaceuticals, but AstraZeneca and Johnson & Johnson have also opened up their wallets this week – welcome to in-Pharmatechnologist.com’s merger & acquisition round-up.
Canadian contract manufacturing and testing firm Garmen Laboratories will be acquired by Cancer drug developer Advanomics Corp in a deal announced today.
Dyax says the entry of its human antibody drug candidate DX-2930 into clinical trials is thanks to successful development and up-scale manufacturing by Laureate Biopharma.
Higher demand for methadone, buprenorphine and opiates coupled with the positive impact of a recent acquisition drove first half growth at Swiss supplier Siegfried.
Amgen has spent $10.4bn (€7.8bn) in acquiring Onyx Pharmaceuticals saying its oncology products and pipeline will be strengthened by Amgen’s manufacturing capabilities.
Jubilant HollisterStier (JHS) says expansion of its sterile manufacturing capacity at its facility in Kirkland, Canada will be used to fulfill several new contracts.
Pfizer has remained the world’s largest public manufacturer of pharmaceuticals, according to an industry report, though dropped revenue in 2012 has left Novartis hot on its heels.
German CMO Rentschler landed APN311 production deal thanks to location and cell culture based manufacturing skills according to BioPharma Apeiron Biologics.
Codexis has denied breaching its licensing deal with Dyadic International and says losing rights to the C1 fungal expression system would hit its CodeXyme business hard.
Consolidating its Indian injectable business under a new subsidiary will improve focus and align quality control, says Aurobindo who has invested in two manufacturing companies to support such plans.
Albany Molecular Research's (AMRI) stock fell more than 10% on Monday after announcing in an SEC filing that it was informed by its partner Bristol-Myers Squibb that it would terminate the development of an investigational depression drug.
ScinoPharm and Sundia MediTech have teamed up to try and win business from international drugmakers that - they say - want to simplify outsourcing to China.
AMRI (Albany Molecular Research Inc.) saw its revenue increase 19% in Q2 compared to the same quarter last year as its discovery services and large scale manufacturing contract revenue spiked by over 20%.
US and foreign generic drug manufacturers will see a more than $40,000 increase in US FDA facility fees for 2014, while API manufacturers will see a more than $8,000 increase.
Piramal is upgrading its ADC (antibody drug conjugate) manufacturing capacity in response to demand from clients in late phase trials looking to ramp up production.
Hospira linked its improved Q2 results to progress made in efforts to address quality problems at various manufacturing plants, but the 483s and Warning Letters are still coming.
NovaMedica and the Russian Government are to build an $85m (€64m) facility as part of a joint venture encouraging local manufacturing, the company says.
Integrated DNA Technologies (IDT) has opened a facility in Singapore in order to manufacture oligonucleotides for research companies throughout the region.
Europe may soon approve the first biologic made according to quality by design (QbD) principles, but opinions are still split over whether the approach should even be applied to biopharmaceuticals.
Appreciating warm alcohol, like being rubbish at cricket, is no longer a solely British preserve with researchers in Australia developing a hot ethanol-based manufacturing method that, they claim, produces smaller, more uniform API particles.
With the Chinese NAP (nucleic acid purification) market expected to grow more than 8% over the next year and no clear market leaders, companies are looking to take control of the industry space.
Biopharma firms, particularly those producing insulin and five of its analogues, have another option in the market of sub-2 micron solid-core chromatography columns with a recent offering from Waters.
